FDA studying deaths of two patients on Lilly's long-acting Zyprexa

World News
18-06-2013 | 10:49
High views
Share
LBCI
Share
LBCI
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
FDA studying deaths of two patients on Lilly's long-acting Zyprexa
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
0min
FDA studying deaths of two patients on Lilly's long-acting Zyprexa

The U.S. Food and Drug Administration on Tuesday said it was investigating deaths of two patients who died following injections with Eli Lilly and Co's  long-acting treatment for schizophrenia, called Zyprexa Relprevv.

The agency said the patients died 3 to 4 days after receiving an appropriate dose of the medicine.
 
 
REUTERS

Download now the LBCI mobile app
To see the latest news, the latest daily programs in Lebanon and the world
Google Play
App Store
We use
cookies
We use cookies to make
your experience on this
website better.
Accept
Learn More